Assessment of Atrial Late Potentials in Patients with Hypertention to Investigate the Preventive Effect of Eplerenone on Atrial Fibrillation.
Not Applicable
- Conditions
- Hypertention
- Registration Number
- JPRN-UMIN000006343
- Lead Sponsor
- Osaka General Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who have a contraindication to Selara TAB administration. 2. Patients who have a contraindication to Norvasc TAB administration . 3. Patients with liver dysfunction (AST or ALT values of >=100IU). 4. Patients who are judged by the investigator to be not eligible for enrollment in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in atrial late potentials recorded by P wave signal-averaged ECG.
- Secondary Outcome Measures
Name Time Method 1. Correlation between baseline characteristics and atrial late potentials. 2. Correlation between change in atrial late potentials and change in blood biomarkers.